The metabolism and excretion of N-(3R) 
Radioisotope use in biopharmaceutical research has been invaluable in definitively elucidating test compound excretory and metabolic pathways in animals (Dalvie, 2000) . The most common radionuclide used for these studies is 14 C because of its synthetic versatility, safety relative to other radioisotopes, and favorable nuclear properties dictating optimal half-life and specific activity (McCarthy, 2000) . However, in certain instances, 3 H has been used instead of (or in addition to) 14 C to attain in vitro (Guroff et al., 1967; Kler et al., 1992; Linnet, 2004) and in vivo (Prakash et al., 1997; Ehlhardt et al., 1998; Koller-Lucae et al., 1999; Rosenborg et al., 1999; Gray et al., 2001 ) biotransformation data. Due to the general synthetic ease, low cost, and rapid turnaround of 3 H incorporation (Saljoughian and Williams, 2000) , such high specific activity compounds are desirable when radiolabeled material is needed quickly to answer particular metabolism-related questions during drug discovery or development. Although a compound's 14 C atom may become separated from the substructure retained by the majority of metabolites because of its incorporation at a metabolically labile site (Chasseaud et al., 1974; Hawkins et al., 1977; Larsson and Lund, 1981) , there is no concern of its passive chemical exchange leading to nonradiolabeled compound and/or metabolites. Conversely, due to the intrinsic properties of the hydrogen atom, 3 H exchange within a molecule may occur readily in aqueous physiological environments of varying pH by chemical (e.g., ␣-H exchange during keto-enol tautomerization) or metabolic means (Lewis et al., 1988) . In either case, 3 H exchange ultimately affords tritiated water (HTO), the molecular reporter of 3 H loss, resulting in both the absence of radiotracer capabilities from the test compound and/or its metabolites and ambiguous biotransformation data. Hence, the predominant risk associated with using 3 H-labeled compounds in biological systems is the potential chemical and metabolic instability of the 3 H atom itself at its specific site within the test molecule. For instance, when profiling in vitro or in vivo samples containing 3 H metabolites requiring identification, formed HTO might be detected radiochromatographically within the solvent front, potentially resulting in its erroneous identification as a highly polar (and possibly significant) metabolite. Likewise, ambiguity might arise when calculating 3 H recovery from biofluids undergoing organic extraction; low organic phase 3 H levels may be ascribed to highly polar metabolites, HTO, or both. For total radioactivity PK analyses, 3 H exchange causes similar data interpretation complexities as a result of tritium's threecomponent exponential function biological half-life, ranging from 10 to 300 days in humans (Robertson, 1973) . If 3 H exchange occurs, the total radioactivity AUC is useless because its terminal phase can be attributable to HTO and not necessarily drug-related material (Kim et al., 2004) . Therefore, to use 3 H compounds effectively for drug metabolism studies, one must not only strategically select the theoretically most chemically and metabolically stable molecular site for 3 H incorporation but also seek empirical confirmation by quantifying HTO within all samples via lyophilization to determine the true inertness of the 3 H atom. With these issues in mind, 1, an agonist of the ␣ 7 nicotinic acetylcholinergic receptor (Wishka et al., 2006) , was selectively monotritiated for radiolabeled mass balance studies in Sprague-Dawley rats and beagle dogs. Initially, [ 3 H]1a ( Fig. 1 ) was generated because of synthetic ease, and its suitability in both species was evaluated in pilot studies by determining 3 H recovery in lyophilized urine and feces and 3 H AUC using nonlyophilized plasma. Only 80% mass balance was achieved in rats with urinary HTO, accounting for 4% of recovered dose, whereas 95% mass balance was attained in dogs with no detection of HTO. Furthermore, [ 3 H]1a afforded total radioactivity half-lives of 133 and 5 h in rats and dogs, respectively (Fig. 2) . The incredibly long half-life in rats was indicative of very slowly eliminated metabolite(s) and/or HTO formed from drug-derived material attributable to site-specific chemical and/or metabolic 3 H instability (Fig. 3) 96, 21.35, 24.09, 39.35, 44.91, 46.19, 46.63, 52.25, 125.51, 133.98, 137.08, 140.57, 155.26, 167.52, 178.69 19, 21.51, 24.56, 43.88, 45.22, 45.60, 50.73, 122.18, 124.62, 136.79, 139.26, 163.61, 164.77, 169.10 26, 25.35, 26.66, 63.12, 63.48, 68.82, 72.32, 108.15, 117.26, 133.73, 136.75, 144.51, 151.69, 155.23, 167.30 All animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, and all study animals were fasted overnight before compound administration and for 4 h postdose. Individual animal doses were calculated based on respective pretreatment body weights and a dose volume appropriate for the specific species. The actual amount of dose solution administered to each animal was determined by weighing the loaded dosing syringe before and after it was dispensed.
[ 3 H]1a in Sprague-Dawley Rats. A single dose (8 mg/kg, 400 Ci) of [ 3 H]1a in citrate buffer (50 mM, pH 5) was administered via oral gavage to intact male rats. The study included two groups of rats: in group 1 (two males), urine, feces, and cage rinse were collected from animals predose and in 24-h intervals over 4 days postdose; and, in group 2 (one per time point), blood samples from animals euthanized predose and at 0.5, 2, and 8 h postdose were collected by exsanguination after cardiac puncture into tubes containing Na 2 EDTA and processed to obtain plasma.
[ 3 H]1a in Beagle Dogs. A single dose (15 mg/kg, 640 Ci) of [ 3 H]1a in citrate buffer (50 mM, pH 5) was administered orally to a single intact male dog. From this one dog, excreta and cage debris/rinse were collected predose and in 24-h intervals over 2 days, whereas blood samples (approximately 6 ml) were collected into heparinized tubes via venipuncture of a cephalic or jugular vein predose and at 0.5, 1, 2, 4, 8, and 24 h postdose and processed to obtain plasma.
[
]1b in citrate buffer (50 mM, pH 5) was administered via oral gavage to each intact rat. The study included two groups of rats: in group 1 (four per sex), from intact animals, urine was collected predose and from 0 to 12 and 12 to 24 h during day 1 and in 24-h intervals from 24 to 168 h postdose. From the same animals, feces and cage rinse were collected predose and in 24-h intervals from 0 to 168 h postdose, and in group 2 (one/sex/time point), blood samples from intact animals euthanized predose and at 0.5, 1, 2, 4, 8, and 24 h postdose were collected by cardiac puncture into tubes containing Na 2 EDTA and processed to obtain plasma.
[ 3 H]1b in Beagle Dogs. A single dose (10 mg/kg, 480 Ci) of [ 3 H]1b in citrate buffer (50 mM, pH 5) was administered orally to intact dogs (two per sex) from which excreta and cage debris/rinse were collected as described for [ 3 H]1b in rats. Blood samples (approximately 6 ml) were collected into heparinized tubes via venipuncture of a cephalic or jugular vein predose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 , and 24 h postdose and processed to obtain plasma. Control plasma was harvested from blood collected from untreated dogs.
Determination of Radioactivity within Urine and Plasma from Animals Receiving [
3 H]1a. Due to the exploratory nature of the [ 3 H]1a studies, only urine was subjected to lyophilization to determine its HTO concentration. Therefore, duplicate nonlyophilized gravimetric aliquots of urine (0.5 g) and plasma (0.1 g) from each time point were mixed with Ultima Gold (PerkinElmer Life and Analytical Sciences, Inc., Wellesley, MA) liquid scintillation cocktail (15 ml) and counted for 2 min by a Packard Tri-Carb 1900CA or 2300TR liquid scintillation counter (Packard BioScience, Co., Meriden, CT). In parallel, duplicate gravimetric aliquots (2 g) of urine from each time point were frozen, lyophilized using a FreeZone 4.5 Benchtop Freeze Dry System (Labconco Corp., Kansas City, MO), reconstituted in Milli-Q H 2 O (0.2 g) and liquid scintillation cocktail (15 ml), and analyzed for total radioactivity by LSC for 2 min. The difference in total radioactivity within each urine sample before and after lyophilization was attributed to HTO. Scintillation counter data were automatically corrected for counting efficiency using an external standardization technique and an instrument-stored quench curve generated from a series of sealed quench standards.
3 H]1b. The following procedure was undertaken to quantify both total radioactivity and HTO within each urine and plasma sample: triplicate gravimetric aliquots (0.2-0.5 g for urine, 0.05 g for plasma) from each time point were mixed with TruCount scintillation cocktail (15 ml) and counted for 2 min by a model LS 6000 or LS 6500 liquid scintillation counter (Beckman Coulter, Inc., Fullerton, CA). In parallel, triplicate gravimetric aliquots of similar mass from each time point were frozen, lyophilized, reconstituted, and analyzed for total radioactivity as described previously. The difference in total radioactivity within each sample without and with lyophilization was ascribed to HTO. Scintillation counter data were automatically corrected for counting efficiency as described for O) were homogenized directly with a probe-type homogenizer. Triplicate gravimetric aliquots (0.4 -0.7 g for either homogenate) were transferred into tared cones and pads, weighed, dried for a minimum of 24 h at ambient temperature, and combusted before radioanalysis. Sample combustion was performed using a Packard Instruments model A0387 sample oxidizer (Packard BioScience). Combustion efficiency using a 3 H standard was determined daily before the combustion of study samples, and the measured radioactivity content in feces and cage debris/rinse was adjusted using daily combustion efficiency values. Liberated HTO was trapped in Monophase-S (Perkin Elmer Life and Analytical Sciences), mixed in Perma-Fluor-E scintillation fluid (Packard BioScience), and quantified in a model LS 6000 or LS 6500 liquid scintillation counter (Beckman Coulter, Inc.) for 10 min. All combustion- 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org related scintillation counter data were corrected for counting efficiency as explained previously. Pharmacokinetic Calculations. PK parameters were calculated for each gender (rats) or animal (dogs) by noncompartmental analyses using WinNonlin version 3.2 (Pharsight Corp., Mountain View, CA). Values used to determine total radioactivity PK parameters were calculated by converting the raw data generated by LSC to concentrations (ng-Eq/ml) using the specific activity of administered [
3 H]1a or [ 3 H]1b. The AUC 0-tlast was calculated using the linear trapezoidal method, k el was determined by linear regression of the log concentration-versus-time data during the last observable elimination phase, and half-life (t 1/2 ) was calculated as 0.693/k el . Both C max and the time of its occurrence (T max ) were taken directly from the concentration-versus-time data. Means and standard deviations were calculated when half or greater of the values exceeded the lower limit of quantification for total radioactivity (2 and 10 ng-Eq/ml for rats and dogs, respectively). A value of 0 was used when a measured value was less than the lower limit of quantification.
Preparation of [ 3 H]1b Samples for Metabolite Profiling and Identification. At each step during the sample preparation of all biological matrices, total radioactivity levels were determined by LSC for recovery calculations. After preparation, all samples were analyzed as described below by LC-MS/MS with radiometric detection. Predose and blank samples served as controls for determining background radioactivity and endogenous, nondrug-related ions observed within respective matrices or their extracts by LC-MS/MS.
Urine. LSC analysis of both pre-and postlyophilization urine samples for each time point from each animal found no significant difference (i.e., Ϯ5%) in the amount of radioactivity contained within each sample suggesting that no appreciable amount of HTO was contained within this matrix. Thus, nonlyophilized urine samples from each rat (collected from 0 -48 h postdose representing Ͼ93% of total urine radioactivity) and dog (0 -24 or 0 -48 h samples, Ͼ95% of total urine radioactivity) were pooled proportional to the amount of urine in each sampling period to afford the analytical sample.
Feces. Due to minimal amounts of fecal radioactivity recovered from dogs (Ͻ3% of dose), only rat feces were profiled. Fecal homogenates (6 to 14 g) from each rat collected from 0 to 48 h postdose, representing Ͼ94% of total fecal radioactivity were pooled proportional to the amount of feces in each sampling period. Pooled homogenates were diluted with acetonitrile (MeCN; 2 ml/g homogenate), vortex-mixed, and centrifuged (1811 rcf for 10 min), and the resulting supernatants were isolated. If necessary, the remaining fecal pellets were extracted further with 40% H 2 O in MeCN (4 ϫ 6 ml) until Ͼ90% of the radioactivity from each pooled sample was recovered. The supernatants were concentrated to near dryness and reconstituted in 30% MeCN in 10 mM ammonium formate, pH 3.4 (750 l; solvent A) for analysis. Although fecal homogenates did not undergo lyophilization for the determination of HTO content, HTO within analytical samples was evaluated by monitoring the elution of a peak within or close to the solvent front of the radiochromatogram. In all rat fecal extracts analyzed, no radioactive peak corresponding to Ն1% of the administered dose was observed within the radiochromatogram during the first 15 min after injection.
Rat Plasma. Nonlyophilized plasma from blood samples collected at 0.5, 1, 2, 4, and 8 h postdose were used for circulatory metabolite profiling and identification because approximately 90% of the lyophilized total radioactivity AUC 0 -24 was captured by its AUC 0 -8 , and approximately 80% of the total nonlyophilized radioactivity AUC 0 -8 was captured by its lyophilized AUC 0 -8 , suggesting little contribution to the nonlyophilized total radioactivity AUC 0 -8 by HTO. Plasma samples were pooled within gender according to the method of Hamilton et al. (1981) ; i.e., 17, 25, 50, 100, and 67 l, respectively, of plasma from each time point sample were combined to afford 259 l of pooled plasma for each gender profile. To remove dissolved proteins, the male and female pooled plasma samples were diluted with MeCN (1.04 ml), vortexmixed for 30 min, and centrifuged (2465 rcf for 10 min), and the resulting supernatants, which contained Ͼ83% of the radioactivity from each pooled plasma sample, were isolated. Each supernatant was concentrated to near dryness at 35°C under N 2 , and reconstituted in solvent A (150 l) for analysis. Dog Plasma. Nonlyophilized plasma from blood samples collected at 0.25, 0.5, 1, 2, 3, 4, and 6 h postdose were used for circulatory metabolite profiling and identification because approximately 90% of the total radioactivity AUC 0 -12 was captured by its AUC 0 -6 using either nonlyophilized or lyophilized sample data, and approximately 100% of the total nonlyophilized radioactivity AUC 0 -6 was captured by its lyophilized AUC 0 -6 , suggesting no HTO contribution to the nonlyophilized total radioactivity AUC 0 -6 . Plasma samples were pooled as described above such that 125, 375, 750, 1000, 1000, 1500, and 1000 l, respectively, of plasma from each time point sample per animal were combined. Thus, because two dogs per sex were dosed, a total of 11.5 ml of pooled plasma was obtained for each gender profile. The pooled plasma samples were diluted with MeCN (23 ml), vortex-mixed for 30 min, and centrifuged (2465 rcf for 10 min), and the resulting supernatants, which contained Ͼ94% of the radioactivity from each pooled plasma sample, were isolated. Each supernatant was concentrated to near dryness at 35°C under N 2 , and reconstituted in solvent A (300 l) for analysis.
Metabolite Profiling and Identification Using [ 3 H]1b Samples. Samples were analyzed by an LC-MS/MS, comprised of a PE Sciex API-3000 tandem quadrupole mass spectrometer with a Turbo Ionspray interface (Perkin Elmer Life and Analytical Sciences), two Shimadzu LC-10A HPLC pumps (Shimadzu USA, Columbia, MD), and a CTC PAL Autosampler (LEAP Technologies, Carrboro, NC), in series with a Beta-RAM radiometric detector (IN/US Systems, Inc., Tampa, FL) containing a liquid scintillant cell (500 l). Analytes within sample aliquots (20 -100 l) were eluted on a Phenomenex Luna Phenyl-hexyl analytical column (5 , 4.6 ϫ 250 mm) at 1 ml/min with 10 mM ammonium formate, pH 3.4 (solvent B), and MeCN (solvent C). The following two-step gradient was used: 0 to 10 min, 2% solvent C in solvent B; 10 to 30 min, 2 to 35% C in B; and 30 to 32 min, 35 to 90% C in B. After the elution of 1 and its metabolites, the column was washed with 90% C in B for 3 min and then returned over 3 min to 2% C in B where it remained for 7 min before the next injection. For each matrix, Ͼ94% of the radioactivity injected onto the column eluted during the first 32 min of the gradient program. HPLC effluent was split 1:9 between the mass spectrometer and the radiometric flow detector; liquid scintillation cocktail flowed at 3 ml/min to the radiometric detector. Mass spectral data were collected using positive ionization in full, precursor ion, neutral loss, product ion, and multiple-reaction monitoring scanning modes. Instrument settings and potentials were adjusted to provide optimal data in each mode. Masschrom version 1.1.1 (Perkin Elmer Life and Analytical Sciences) and Winflow version 1.4 (IN/US Systems, Inc.) software were used for the acquisition and processing of mass spectral and radiochromatographic data, respectively. -derived data, total radioactivity plasma concentration-versus-time curves are plotted in Fig. 2 , and PK parameters are listed in Table 2. For [ 3 H]1b-related data, all reported PK parameters (Table 2) are an average of genders as a result of no readily apparent gender-related differences in systemic exposures to total radioactivity; average total radioactivity plasma concentration-versustime curves for both nonlyophilized and lyophilized plasma are plotted in Fig. 4. For [ 3 H]1b, mean total radioactivity T max and C max were identical for nonlyophilized and lyophilized plasma samples, whereas the nonlyophilized plasma t 1/2 was greater (31 versus 24 h). Interest-ingly, [ 3 H]1b total radioactivity AUC ratios of lyophilized versus nonlyophilized plasma decreased for AUC 0 -8 (0.8), AUC 0 -24 (0.5), and AUC 0-ϱ (0.2), suggestive of HTO within nonlyophilized plasma from blood drawn at later time points postdose, which rationalizes the longer nonlyophilized plasma t 1/2 . If HTO was indeed present in plasma, it must have arisen from a minimal amount of drug-related material since Ͻ1% of the [ 3 H]1b dose detected in rat urine was attributable to HTO, and overall mass recovery was high (93%).
Results

Excretion of Total Radioactivity in Rats and
A comparison of [ 3 H]1a (8 mg/kg) to [ 3 H]1b (5 mg/kg) nonlyophilized plasma total radioactivity PK parameters clearly shows a significant difference in total radioactivity exposure (Table 2 ). Although T max was identical and C max was dose-proportional for both radioisomers, total radioactivity AUC ratios for [
3 H]1a versus [ 3 H]1b increased nonlinearly for AUC 0 -8 (4.5) and AUC 0-ϱ (28). Therefore, nonlyophilized plasma total radioactivity half-lives for [
3 H]1a and [ 3 H]1b were 133 and 31 h, respectively, with the former being consistent with that of 85 to 98 h, reported previously for HTO in rats (Richmond et al., 1962; Foy, 1964; Wheeler et al., 1972 , total radioactivity plasma concentration-versus-time curves are plotted in Fig. 2 , and PK parameters are listed in Table 2. For [ 3 H]1b-related data, all reported PK parameters ( Table 2) are an average of genders as a result of no readily apparent gender-related differences in systemic exposures to total radioactivity; average total radioactivity plasma concentration-versus-time curves for both nonlyophilized and lyophilized plasma are plotted in Fig. 5 3 H]1b (10 mg/kg), consistent with linear PK for total radioactivity; identical T max and similar t 1/2 were also observed. These PK data, supplemented by the absence of HTO in excreta and full mass recovery in both dog studies, confirmed the 163, 146, 118, 110, and 82 (Fig. 6 ). Therefore, precursor ion scanning of diagnostic fragment ions m/z 118 and 110 determined if metabolites of 1 were modified on its quinuclidine or furanopyridine moieties, respectively. A summary of all metabolite LC-MS/MS data is found in Table 3 . The identification of a metabolite as a synthetic standard was determined by the compounds' indistinguishable CID spectra and LC t R , as well as an increase in metabolite MS peak height upon the addition of the authentic standard to the analytical sample. Quantitative Profile of [ 3 H]1b and Its Metabolites in Rat and Dog Excreta and Plasma. In addition to 1, six metabolites were observed in rat urine and five in rat feces (Table 4) . Three metabolites were tentatively identified as pyridinyl-␣-hydroxy acetic acid (M1), dihydroxy-ethyl-pyridinol (M2), and hydroxyl-ethyl-pyridinol (M3), whereas the other three metabolites were 2, 3, and 4. In dog urine, 1, 2, and 4 were detected. On average in rat and dog urine, 40.0 and 9.3%, respectively, of the dose was unchanged 1.
In addition to 1, metabolites 2, M3, 3, and 4 were identified in rat plasma, whereas only 2 and 4 were observed in dog plasma (Table 4) . On average in plasma, 1 comprised 29.7 and 10.1% of total circulatory radioactivity in rats and dogs, respectively.
Discussion
Due to the cited caveats for using 3 H compounds in radiolabeled biotransformation studies, 3 H stability within [ 3 H]1a was first evaluated in rat and dog pilot studies by monitoring its 3 H recoveries in excreta (Table 1) and nonlyophilized plasma radioactivity PK curves (Fig. 2) . These studies generated contrasting results, with rat and dog total 3 H half-lives of 133 and 5 h, respectively. Although the extensive half-life in rats could hypothetically be attributed to long-lived circulatory metabolites, it seemed more reasonably explained by HTO, which has a reported half-life of 85 to 98 h in rats (Richmond et al., 1962; Foy, 1964; Wheeler et al., 1972) , formed by 3 H loss from [ 3 H]1a; this was confirmed by urinary HTO and low overall mass recovery. The short total radioactivity half-life and high mass recovery in dogs, both indicative of no HTO generation as confirmed by lyophilized urine, further suggested that 3 H loss in rats was due to a species-specific difference in the metabolism of [ 3 H]1a. These data and the known metabolic vulnerability of furans (Dalvie et al., 2002) prompted the radiosynthesis of [
3 H]1b with strategic monotritiation at a site envisaged to be both chemically and metabolically inert. Subsequent mass balance studies were conducted with [ 3 H]1b in both species with expected lower, yet very relevant, 3 H exchange risk that was evaluated by HTO quantification within urine and plasma via lyophilization.
The metabolic and excretory pathways of 1 in rats and dogs were determined definitively using [ 3 H]1b, with Ն86% of administered radioactivity recovered on average in both species (Table 1) . Lyophilization demonstrated in both species that HTO contributed to Ͻ1% of the dose recovered in urine. It also detected HTO in rat plasma after 8 h postdose but not in dog plasma over 24 h (Table 2 ). For rats, the insignificant amount of HTO in urine, the predominant route of radioactivity excretion, suggested essentially complete 3 H retention within [ 3 H]1b in vivo. Nonetheless, enough HTO (beyond experimental error) was present in rat plasma to show meaningful differences in radioactivity PK curves for nonlyophilized versus lyophilized samples (Fig. 4) ; HTO formation from [ 3 H]1b is proposed by H/ 3 H exchange via resonance of oxygen lone pair electrons with C 7 in pyridinol metabolites. The longer turnover half-time of HTO relative to 1 and its metabolites resulted in an increasing HTO-related contribution to total circulatory radioactivity over time. This phenomenon manifested in an extended terminal phase of the nonlyophilized total radioactivity plasma PK curve, which is conspicuously absent in that from lyophilized plasma because of the physical removal of HTO during the freeze-drying process. This observation stresses the need to lyophilize all plasma samples when conducting 3 H-labeled drug metabolism studies since lyophilized samples ensure the true AUC and k el of non-HTO-related radioactivity.
Proposed metabolic pathways, incorporating customary furan biotransformation mechanisms (Schmid et al., 1980; Kobayashi et al., 1987; Sahali-Sahly et al., 1996) , of 1 in rats and dogs are presented in Fig. 7 . Within both species, the two metabolically susceptible sites in 1 were its quinuclidine to afford 4 and its furanopyridine to generate all other metabolites. Definitive metabolite elucidation for 1 using (Fig. 3, paths a and c) and/or metabolism-mediated ex- atom, facile 3 H exchange, which may readily afford a 3 H compound synthetically, is often the culprit for compound unacceptability for biotransformation studies. To ascertain this "exchange risk" quantitatively, all biological samples must undergo lyophilization to determine their HTO content, the amount of which determines unequivocally the suitability of the tritiation site from a biotransformation standpoint. Although 3 H-labeled compounds may instinctively be more cost effective and time efficient to synthesize than their 14 C brethren, such compounds from a metabolism perspective are only as good as the chemical and metabolic stability of their tritium atom.
